Selinger M, Mackenzie I Z, Gillmer M D, Phipps S L, Ferguson J
Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Headington, Oxford, UK.
Br J Obstet Gynaecol. 1987 Dec;94(12):1218-22. doi: 10.1111/j.1471-0528.1987.tb02325.x.
A double-blind, placebo controlled clinical trial was conducted to assess the clinical and physiological effects of 'epostane', a progesterone synthesis inhibitor, in mid-trimester prostaglandin termination of pregnancy. Mean peripheral progesterone levels had fallen by 74% after 72 h in the patients treated wtih epostane. The mean induction-abortion interval in the treatment group was 490 (SD 271) min, compared with 1432 (SD 640) min in the control group. Intrauterine pressure recording demonstrated increased sensitivity to prostaglandin E2 after epostane treatment but no change in oxytocin sensitivity. The clinical implications of facilitated induction of abortion are discussed.
进行了一项双盲、安慰剂对照临床试验，以评估孕酮合成抑制剂“依波斯坦”在孕中期前列腺素终止妊娠中的临床和生理作用。接受依波斯坦治疗的患者在72小时后外周孕酮平均水平下降了74%。治疗组的平均引产-流产间隔为490（标准差271）分钟，而对照组为1432（标准差640）分钟。子宫内压力记录显示，依波斯坦治疗后对前列腺素E2的敏感性增加，但对催产素的敏感性无变化。文中讨论了引产更容易的临床意义。
